STARD3NL Antibody

What is STARD3NL and what cellular functions does it perform?

STARD3NL (STARD3 N-Terminal Like) is a tethering protein that creates contact sites between the endoplasmic reticulum and late endosomes. It primarily localizes to late endosome membranes and interacts with the endoplasmic reticulum via binding with VAPA and VAPB proteins . The protein contains a MENTAL domain with an FFAT-like motif that facilitates these interactions, providing favorable environments for molecular exchange and specific metabolic activities . With a calculated molecular weight of 27 kDa and 234 amino acids, STARD3NL (also known as MENTHO or MLN64 N-terminal domain homolog) plays significant roles in cellular trafficking and signaling pathways . Recent research has identified its importance in bone metabolism, where it functions as a negative regulator of osteogenic differentiation through interactions with the Wnt signaling pathway .

What are the validated applications for STARD3NL antibodies in experimental research?

STARD3NL antibodies have been validated for multiple experimental applications, each with specific optimization parameters:

These applications have been successfully demonstrated in multiple experimental systems, including human breast cancer tissue, U2OS cells, HEK-293 cells, and mouse kidney tissue . Researchers should note that optimal dilutions may be sample-dependent and should be determined empirically for each experimental system.

How should samples be prepared for optimal STARD3NL antibody performance?

For optimal performance with STARD3NL antibodies, sample preparation protocols should be tailored to the specific application. For Western blot analysis, cell lysates should be prepared using RIPA buffer supplemented with protease inhibitors on ice . Proteins should be denatured and separated via 10% SDS-PAGE before transfer to nitrocellulose membranes . For immunohistochemistry applications with paraffin-embedded tissues, antigen retrieval with TE buffer at pH 9.0 is recommended, though citrate buffer (pH 6.0) may serve as an alternative . When performing immunofluorescence studies, fixation protocols should preserve the native subcellular localization of STARD3NL, particularly at endosomal membranes. For immunoprecipitation studies, gentler lysis conditions may be preferable to maintain protein-protein interactions, especially when investigating STARD3NL's binding partners such as Annexin A2 . Storage of the antibody at -20°C is recommended for stability, with aliquoting unnecessary for this storage temperature .

What species reactivity is confirmed for commercially available STARD3NL antibodies?

Commercial STARD3NL antibodies demonstrate reactivity across multiple species, though with variation between specific products:

When selecting an antibody for multi-species studies, researchers should verify the cross-reactivity claims and review validation data for each species of interest . The high sequence homology between human and mouse STARD3NL makes many antibodies suitable for both species, but experimental validation is recommended before conducting extensive studies.

How does STARD3NL function in osteogenic differentiation and what experimental approaches best detect this activity?

STARD3NL has been identified as a negative regulator of osteogenic differentiation through its interaction with the Wnt/β-catenin signaling pathway . Research has revealed elevated STARD3NL expression in bone tissues from patients with low bone mass and in ovariectomized (OVX)-induced osteoporotic mice .

To study this function experimentally, researchers should consider:

• Expression analysis: qPCR using validated primers (forward: 5′-TTGAGTCCTATGAAGGAAGGGAA-3′, reverse: 5′-GCCTCCGTTCACATTTAACTCTA-3′) can quantify Stard3nl expression alongside osteogenic markers like Runx2, Sp7, and Alpl .

• Gain/loss-of-function studies: Lentiviral vectors for overexpression or shRNA knockdown (target sequences: 5′-CCAGTGCCTTTCTATTAGCAA-3′ or 5′-CGATTCAAAGTGCTGATACTT-3′) can manipulate STARD3NL levels to assess effects on osteoblast differentiation and mineralization .

• Protein interaction analysis: Co-immunoprecipitation experiments with STARD3NL antibodies can detect binding partners like Annexin A2, which mediates STARD3NL's effects on Wnt signaling .

• Functional assays: ALP activity assays and Alizarin Red S staining can quantify osteogenic differentiation in response to STARD3NL manipulation .

Detection of STARD3NL's inhibitory effect on β-catenin expression requires careful experimental design, including nuclear-cytoplasmic fractionation to assess β-catenin nuclear translocation and luciferase reporter assays to measure Wnt signaling activity .

What are the optimal conditions for immunoprecipitation studies using STARD3NL antibodies?

For successful immunoprecipitation of STARD3NL and its binding partners, several critical parameters must be optimized:

• Antibody selection: Choose antibodies validated specifically for IP applications. Based on the search results, 0.5-4.0 μg of STARD3NL antibody per 1.0-3.0 mg of total protein lysate is recommended .

• Lysis conditions: RIPA buffer with protease inhibitors provides effective extraction while preserving protein interactions. For more sensitive interactions, consider milder non-ionic detergent buffers .

• Binding conditions: Incubate antibody with lysate overnight at 4°C with gentle rotation to maximize antigen-antibody binding while minimizing non-specific interactions.

• Bead selection: Protein A/G magnetic beads offer advantages over agarose beads for pull-down efficiency and reduced background.

• Washing stringency: Multiple washes with decreasing salt concentrations optimize removal of non-specific proteins while retaining specific interactions.

• Elution methods: Gentle elution with glycine buffer (pH 2.8) followed by immediate neutralization helps preserve co-immunoprecipitated proteins for downstream analysis.

• Controls: Include IgG control, input sample, and unbound fraction analysis to validate specificity.

For detecting STARD3NL interactions with Annexin A2 specifically, researchers should note that this interaction mediates STARD3NL's effects on β-catenin expression and Wnt signaling activity in osteogenic differentiation .

How can researchers validate STARD3NL antibody specificity for their experimental system?

Comprehensive validation of STARD3NL antibody specificity requires multiple complementary approaches:

• Positive and negative control samples: Test the antibody against samples with known STARD3NL expression levels. HEK-293 cells and U2OS cells serve as positive controls, while vector-only transfected cells provide negative controls .

• Molecular weight verification: Confirm detection of the expected 27 kDa band in Western blot applications, comparing against recombinant STARD3NL protein standards .

• Knockdown verification: Perform siRNA or shRNA-mediated knockdown of STARD3NL (using validated sequences as mentioned in section 2.1) and confirm reduced signal intensity .

• Overexpression validation: Compare antibody detection in wild-type cells versus those overexpressing tagged STARD3NL to confirm signal specificity and linearity .

• Cross-reactivity assessment: Evaluate potential cross-reactivity with related proteins, particularly STARD3, which shares structural similarities with STARD3NL.

• Application-specific validation: For IHC applications, include peptide competition assays and isotype controls. For IF applications, co-localization with known endosomal markers validates expected subcellular distribution.

• Multi-antibody concordance: Compare results using antibodies from different sources or those targeting different epitopes of STARD3NL.

These validation steps should be documented with appropriate controls and reported in publications to strengthen experimental credibility.

What is the role of STARD3NL in membrane contact sites, and how can antibodies help elucidate this function?

STARD3NL functions as a critical tethering protein that establishes contact sites between late endosomes and the endoplasmic reticulum (ER) . Through its MENTAL domain containing an FFAT-like motif, STARD3NL binds to VAP proteins (VAPA and VAPB) on the ER membrane while anchoring to late endosomal membranes . These membrane contact sites (MCS) create microenvironments that facilitate molecular exchange and specialized metabolic activities.

To investigate this function using antibodies:

• Co-localization studies: Dual immunofluorescence labeling with STARD3NL antibodies (dilution 1:300-1:1200) and markers for late endosomes (e.g., Rab7, CD63) and ER (e.g., calnexin, PDI) can visualize contact sites .

• Proximity ligation assays: Using STARD3NL antibodies in combination with VAP protein antibodies can detect and quantify in situ protein interactions at membrane contact sites.

• Immuno-electron microscopy: Ultra-structural localization of STARD3NL at membrane contact sites can be achieved using gold-conjugated secondary antibodies against STARD3NL primaries.

• Functional perturbation: Combining antibody-based detection with expression of mutant STARD3NL lacking the FFAT-like motif can demonstrate the functional importance of these domains.

• Live-cell imaging: When combined with fluorescently tagged organelle markers, immunolabeling of STARD3NL in permeabilized cells can reveal dynamic aspects of contact site formation.

These approaches can help resolve how STARD3NL-mediated contact sites contribute to cellular homeostasis and how dysregulation may impact pathological conditions like osteoporosis .

How can researchers troubleshoot non-specific binding when using STARD3NL antibodies?

When encountering non-specific binding with STARD3NL antibodies, researchers should implement a systematic troubleshooting approach:

• Optimize blocking conditions: Increase blocking time (2-3 hours) and test alternative blocking agents (5% BSA, 5% non-fat milk, commercial blocking buffers) to reduce non-specific binding sites.

• Adjust antibody concentration: Titrate antibody dilutions beyond the recommended range (1:1000-1:4000 for WB, 1:50-1:500 for IHC) to identify the optimal signal-to-noise ratio .

• Modify washing procedures: Increase wash duration or number of washes, and consider adding low concentrations of detergent (0.05-0.1% Tween-20) to wash buffers.

• Preabsorb antibody: For tissue with high background, preabsorb the antibody with tissue powder or lysate from non-expressing cells.

• Reduce secondary antibody concentration: Non-specific binding often originates from secondary antibody interactions; dilute secondary antibodies further.

• Check sample preparation: Ensure complete denaturation for Western blot applications and appropriate antigen retrieval for IHC (TE buffer pH 9.0 is recommended for STARD3NL) .

• Evaluate cross-reactivity: Assess potential binding to related proteins in the STARD family by comparing expression patterns with known tissue distribution.

• Control for endogenous biotin/avidin interactions: When using avidin-biotin detection systems, include avidin/biotin blocking steps.

For Western blot applications, reducing primary antibody incubation time or switching membrane type (PVDF vs. nitrocellulose) may also improve specificity. For challenging samples, consider alternative detection methods or more specific antibody clones.

What experimental approaches can effectively demonstrate STARD3NL's interaction with Annexin A2 and its effects on Wnt signaling?

To robustly demonstrate the STARD3NL-Annexin A2 interaction and its impact on Wnt signaling, researchers should employ multiple complementary approaches:

• Co-immunoprecipitation: Using STARD3NL antibodies (0.5-4.0 μg per 1.0-3.0 mg lysate) to pull down protein complexes, followed by Western blot detection of Annexin A2 . Include reverse IP (using Annexin A2 antibodies) to confirm the interaction bidirectionally.

• Proximity ligation assay (PLA): Visualize and quantify endogenous STARD3NL-Annexin A2 interactions in situ using specific antibodies and proximity ligation technology.

• FRET/BRET analysis: For live-cell interaction studies, combine fluorescently tagged STARD3NL and Annexin A2 to measure energy transfer as an indicator of protein proximity.

• GST pull-down assays: Using recombinant GST-tagged STARD3NL to identify interaction domains within Annexin A2.

• β-catenin translocation assessment: Perform nuclear/cytoplasmic fractionation followed by Western blot for β-catenin, comparing wild-type conditions to STARD3NL knockdown or overexpression .

• TOPFlash/FOPFlash reporter assays: Measure Wnt signaling activity using these luciferase reporters in response to STARD3NL manipulation.

• Functional rescue experiments: After STARD3NL knockdown, determine if Annexin A2 knockdown nullifies the effects on Wnt signaling and osteogenic differentiation.

• Target gene expression analysis: Measure expression of Wnt target genes (e.g., Runx2, Sp7, Alpl) using qPCR (primers provided in search result ) in response to STARD3NL/Annexin A2 manipulation.

These approaches collectively provide strong evidence for the mechanistic pathway by which STARD3NL regulates Wnt signaling through Annexin A2 interaction, particularly in the context of osteogenic differentiation .

What are the critical parameters for optimizing Western blot detection of STARD3NL?

For optimal Western blot detection of STARD3NL, researchers should carefully control several critical parameters:

• Sample preparation: Extract proteins using RIPA buffer with freshly added protease inhibitors on ice. Complete denaturation is essential for proper migration of the 27 kDa STARD3NL protein .

• Gel percentage: Use 10-12% SDS-PAGE gels for optimal resolution of the 27 kDa STARD3NL protein .

• Protein loading: Load 20-50 μg total protein per lane, adjusting based on STARD3NL expression levels in your sample.

• Transfer conditions: Semi-dry transfer at 15V for 30 minutes or wet transfer at 100V for 1 hour provides efficient transfer of STARD3NL to nitrocellulose membranes .

• Blocking: 5% non-fat milk in TBST for 1 hour at room temperature provides effective blocking with minimal background.

• Antibody dilution: Primary antibody dilution should be optimized within the 1:1000-1:4000 range (depending on the specific antibody) . Start with manufacturer recommendations and adjust as needed.

• Incubation conditions: Overnight incubation at 4°C with gentle agitation improves specific binding while reducing background.

• Washing stringency: Five washes of 5 minutes each with TBST effectively remove unbound antibody.

• Signal development: For low abundance samples, consider enhanced chemiluminescence detection systems or fluorescent secondary antibodies for improved sensitivity and quantification.

• Positive controls: Include lysates from cells known to express STARD3NL, such as U2OS or HEK-293 cells .

Following these optimization steps will ensure consistent and specific detection of STARD3NL in Western blot applications, with minimal background and high reproducibility.

How can researchers effectively use STARD3NL antibodies in multi-color immunofluorescence studies?

For successful multi-color immunofluorescence studies involving STARD3NL antibodies, researchers should implement the following specialized protocol:

• Antibody selection: Choose a STARD3NL antibody validated specifically for IF applications (recommended dilution 1:300-1:1200) . Verify that the host species differs from other primary antibodies in your panel to avoid cross-reactivity.

• Fixation optimization: 4% paraformaldehyde (15 minutes at room temperature) preserves STARD3NL localization at endosomal membranes. Test methanol fixation if PFA causes high background.

• Permeabilization: 0.1% Triton X-100 for 10 minutes provides adequate access to intracellular STARD3NL without disturbing membrane structures.

• Sequential staining approach: For complex co-localization studies, consider sequential rather than simultaneous antibody incubations to minimize cross-reactivity.

• Co-localization markers: Pair STARD3NL antibodies with markers for:

  • Late endosomes: Rab7, CD63

  • Endoplasmic reticulum: Calnexin, VAPA/B

  • Wnt signaling components: β-catenin

  • Interaction partners: Annexin A2

• Signal amplification: For low-abundance detection, implement tyramide signal amplification while maintaining spatial resolution.

• Controls for multi-color imaging:

  • Single-color controls to establish bleed-through parameters

  • Secondary-only controls for each channel

  • Absorption controls if fluorophores have overlapping spectra

• Image acquisition considerations:

  • Sequential channel acquisition to prevent bleed-through

  • Identical exposure settings for comparative analysis

  • Z-stack imaging to capture the full cellular volume

• Quantitative analysis: Use colocalization coefficients (Pearson's, Mander's) to quantify spatial relationships between STARD3NL and other cellular components.

These specialized approaches enable detailed analysis of STARD3NL's subcellular distribution and interactions, particularly in the context of endosome-ER contact sites and signaling pathway associations .

How is STARD3NL implicated in bone metabolism disorders, and what experimental models best demonstrate this connection?

STARD3NL has emerged as a significant factor in bone metabolism, with direct implications for osteoporosis and related disorders . This connection can be effectively studied through several experimental approaches:

• Clinical samples: Analysis of STARD3NL expression in spinous process biopsies from patients with low bone mass compared to healthy controls reveals significantly elevated expression in pathological conditions . Immunohistochemical staining (1:50-1:500 dilution) can visualize this differential expression .

• Animal models: Ovariectomized (OVX) mice serve as an established model for osteoporosis, showing increased STARD3NL expression that correlates with reduced bone mineral density . Both protein and mRNA levels should be assessed using Western blot and qPCR, respectively.

• Cellular models: Manipulating STARD3NL expression in osteoblastic cell lines (through overexpression or shRNA knockdown) demonstrates its negative regulatory effect on osteogenic differentiation . Key readouts include:

  • Alkaline phosphatase (ALP) activity

  • Mineralization (Alizarin Red S staining)

  • Expression of osteogenic markers (Runx2, Sp7, Alpl)

  • β-catenin levels and nuclear localization

• Mechanistic studies: The STARD3NL-Annexin A2 interaction provides the molecular link to Wnt signaling inhibition . This can be demonstrated through co-immunoprecipitation experiments and functional rescue studies.

• Genetic association studies: SNPs associated with STARD3NL show robust links to osteoporosis-related traits in multiple populations . These genetic markers can identify at-risk individuals and potential therapeutic targets.

The collective evidence from these experimental approaches establishes STARD3NL as a promising therapeutic target for osteoporosis, operating through a novel mechanism involving Annexin A2 binding and Wnt signaling modulation .

What considerations are important when using STARD3NL antibodies in high-throughput screening applications?

Implementing STARD3NL antibodies in high-throughput screening (HTS) applications requires careful optimization to ensure reliability, reproducibility, and meaningful biological insights:

• Antibody validation for HTS format: Before large-scale implementation, validate STARD3NL antibodies specifically for the HTS platform (e.g., microarray, ELISA, automated IF) using positive and negative controls .

• Standardization of protocols: Develop robust, automatable protocols with:

  • Precise antibody concentrations (based on recommended dilutions: WB 1:1000-1:4000, IHC 1:50-1:500, IF 1:300-1:1200)

  • Consistent incubation times and temperatures

  • Automated washing steps

  • Standardized detection methods

• Positive and negative controls: Include within each plate or batch:

  • Positive controls: U2OS or HEK-293 cell lysates/cultures

  • Negative controls: Vector-only transfected cells

  • Gradient controls to establish assay dynamic range

• Miniaturization considerations: When adapting to 384 or 1536-well formats:

  • Optimize surface coatings to maintain cell adherence

  • Adjust antibody concentrations to account for reduced volumes

  • Implement evaporation control measures

• Readout optimization: Select detection methods appropriate for HTS:

  • Fluorescence intensity for expression levels

  • Translocation assays for β-catenin nuclear movement

  • Multiplexed detection for pathway components

• Data normalization strategies: Implement plate-based and batch-based normalization to minimize technical variation.

• Quality control metrics: Establish acceptance criteria:

  • Z'-factor > 0.5 for robust assays

  • Signal-to-background ratio > 5

  • Coefficient of variation < 15%

• Confirmation strategy: Plan secondary, orthogonal assays to validate hits:

  • Western blot validation

  • Functional assays (e.g., ALP activity, mineralization)

  • Gene expression analysis

These considerations ensure that STARD3NL antibodies can be effectively deployed in HTS campaigns, particularly for screening compounds that might modulate STARD3NL's role in osteogenic differentiation or membrane contact site formation .

How should researchers interpret discrepancies in STARD3NL detection between different antibodies and applications?

When faced with discrepant results using different STARD3NL antibodies or across various applications, researchers should implement a structured investigation approach:

• Epitope mapping analysis: Different antibodies target distinct epitopes within the 234 amino acid STARD3NL protein . Compare the immunogens used to generate each antibody:

  • Antibodies recognizing the MENTAL domain may detect different conformational states

  • N-terminal vs. C-terminal targeting antibodies may yield different results if proteolytic processing occurs

• Application-specific factors:

  • Western blot: Denaturation may destroy conformational epitopes

  • IHC: Fixation and antigen retrieval methods significantly impact epitope accessibility (TE buffer pH 9.0 is recommended for STARD3NL)

  • IF: Permeabilization methods affect membrane protein detection

  • IP: Antibody affinity under native conditions varies considerably

• Expression level considerations:

  • Sensitivity differences between antibodies may explain discrepancies in low-expressing samples

  • Dilution optimization may resolve apparent contradictions (WB: 1:1000-1:4000, IHC: 1:50-1:500)

• Post-translational modifications:

  • Phosphorylation or other modifications may mask epitopes differentially

  • Evaluate whether treatments affecting protein modification resolve discrepancies

• Cross-reactivity assessment:

  • Test for cross-reactivity with related proteins, particularly STARD3

  • Validate specificity using STARD3NL knockout or knockdown samples

• Resolution strategies:

  • Use multiple antibodies targeting different epitopes

  • Employ orthogonal detection methods (mRNA expression, tagged constructs)

  • Consider the biological context of each application

• Data interpretation framework:

  • Give greater weight to results validated across multiple antibodies

  • Consider the validated applications for each antibody (WB, IHC, IF/ICC, IP)

  • Evaluate the biological plausibility of each result in context

By systematically addressing these factors, researchers can resolve apparent contradictions and develop a more complete understanding of STARD3NL biology across experimental systems.

What strategies can help overcome detection challenges in tissues with low STARD3NL expression?

Detecting STARD3NL in tissues with low expression levels presents significant challenges that can be addressed through several specialized approaches:

• Sample enrichment techniques:

  • Perform subcellular fractionation to isolate late endosomal membranes where STARD3NL localizes

  • Use immunoprecipitation to concentrate STARD3NL before detection

  • Implement tyramide signal amplification for IHC/IF applications

• Signal amplification methods:

  • For Western blot: Use high-sensitivity ECL substrates or fluorescent detection with signal accumulation

  • For IHC: Implement polymer-based detection systems or biotinyl tyramide amplification

  • For IF: Consider quantum dot conjugates for improved signal-to-noise ratio

• Optimized sample preparation:

  • For Western blot: Load higher protein amounts (up to 100 μg)

  • For IHC: Optimize antigen retrieval with TE buffer pH 9.0 as recommended

  • For IF: Extend primary antibody incubation (overnight at 4°C)

• Instrument sensitivity adjustments:

  • For Western blot: Extend exposure times or use more sensitive imaging equipment

  • For microscopy: Use cameras with higher quantum efficiency and implement image stacking

• Alternative detection approaches:

  • Consider RNAscope for mRNA detection when protein levels are below antibody detection limits

  • Use proximity ligation assay to detect STARD3NL interactions, which can provide signal amplification

  • Implement mass spectrometry-based targeted proteomics for absolute quantification

• Genetic manipulation strategies:

  • Compare wild-type samples to STARD3NL knockdown controls to confirm specificity of low signals

  • Use CRISPR activation systems to slightly upregulate endogenous STARD3NL for validation studies

• Specialized antibody approaches:

  • Pool multiple validated antibodies targeting different epitopes

  • Consider direct fluorophore conjugation to eliminate secondary antibody background

These approaches, individually or in combination, can overcome the challenges of detecting STARD3NL in tissues with naturally low expression levels or in pathological conditions where expression may be altered.

How might STARD3NL antibodies be utilized in developing therapeutic approaches for osteoporosis?

STARD3NL antibodies can play pivotal roles in developing novel therapeutic approaches for osteoporosis through several research pathways:

• Target validation studies: STARD3NL antibodies can confirm the elevated expression of this protein in patient bone tissue samples and animal models of osteoporosis . Immunohistochemical analysis (using dilutions of 1:50-1:500) can verify STARD3NL as a therapeutic target by demonstrating its correlation with disease severity .

• Mechanism elucidation: Antibody-based techniques including co-immunoprecipitation can further characterize the STARD3NL-Annexin A2 interaction and its downstream effects on Wnt signaling . This mechanistic understanding is crucial for rational drug design targeting this pathway.

• High-throughput screening: STARD3NL antibodies can be utilized in screening assays to identify small molecules or peptides that:

  • Disrupt the STARD3NL-Annexin A2 interaction

  • Reduce STARD3NL expression or stability

  • Block STARD3NL's inhibitory effect on Wnt signaling

• Therapeutic antibody development: Research-grade antibodies that block STARD3NL function could be evolved into therapeutic candidates through:

  • Humanization of promising blocking antibodies

  • Fragment-based approaches (Fab, scFv) for improved tissue penetration

  • Antibody-drug conjugates targeting STARD3NL-expressing cells

• Biomarker development: STARD3NL antibodies could be utilized in developing diagnostic assays to:

  • Identify patients most likely to benefit from STARD3NL-targeted therapies

  • Monitor treatment efficacy through detecting changes in STARD3NL levels

  • Stratify patients based on STARD3NL expression patterns

• Nanoparticle-based delivery systems: Antibodies against STARD3NL could guide targeted delivery of:

  • siRNA/shRNA for STARD3NL knockdown

  • Wnt pathway activators to bone tissue

  • Osteogenic differentiation promoters

The research showing STARD3NL's inhibitory effect on osteogenic differentiation via Wnt signaling suppression provides a strong rationale for these therapeutic approaches . Development of interventions that neutralize STARD3NL activity could potentially promote bone formation and represent a novel treatment strategy for osteoporosis.

What novel applications of STARD3NL antibodies might emerge from its role in membrane contact sites?

The specialized function of STARD3NL in creating and maintaining endosome-ER membrane contact sites opens several innovative research applications for STARD3NL antibodies:

• Super-resolution microscopy of contact sites: Using STARD3NL antibodies in combination with VAPA/B antibodies for STORM or PALM microscopy can reveal the nanoscale organization of contact sites . This approach requires highly specific antibodies (dilutions 1:300-1:1200) suitable for super-resolution techniques .

• Proximity proteomics applications: STARD3NL antibodies can be used for:

  • BioID or APEX2 fusion protein purification to identify novel components of contact sites

  • Proximity labeling of proteins at contact sites followed by mass spectrometry

  • Selective isolation of contact site membrane fractions for proteomic analysis

• Live-cell dynamics of contact sites: Developing non-perturbing antibody fragments (Fab, nanobodies) against STARD3NL for live-cell imaging to study:

  • Contact site formation kinetics

  • Relationship to endosomal maturation

  • Response to cellular stressors or therapeutic agents

• Correlative light and electron microscopy (CLEM): STARD3NL antibodies can bridge fluorescence and electron microscopy to visualize contact site ultrastructure in relation to functional protein complexes.

• Therapeutic targeting of contact sites: As membrane contact sites emerge as important cellular regulatory hubs, STARD3NL antibodies could help develop:

  • Contact site-modulating therapeutics for diseases involving dysregulated endosomal trafficking

  • Targeted delivery systems exploiting contact site biochemistry

  • Diagnostic tools for contact site-related pathologies

• In vivo visualization of contact sites: Development of imaging agents based on STARD3NL antibody fragments that can:

  • Assess contact site dynamics in animal models

  • Evaluate interventions targeting membrane contact sites

  • Study tissue-specific variation in contact site architecture

• Synthetic biology applications: STARD3NL antibodies can help characterize engineered contact sites designed to:

  • Create novel cellular compartments for biotechnology

  • Enhance lipid transfer for metabolic engineering

  • Establish artificial signaling hubs for cellular reprogramming